Entera Health

COVID-19 Studies

Managing Systemic Inflammation and the Symptoms of COVID-19

Disrupting the Binding of ACE2 to COVID-19 Spike Protein

Learn how our team of experts worked to determine if serum-derived bovine immunoglobulin (SBI) is able to bind to the SARS-CoV-2 RBD protein and disrupt RBD-ACE2 binding, preventing viral entry
in cells.

Inhibiting Proteolysis of COVID-19
Spike Protein

Read more about how our team of scientists were able to determine if serum-derived bovine immunoglobulin (SBI) is able to inhibit proteolytic cleavage of the SARS-CoV-2 spike protein S2’ domain by TMPRSS2.

EnteraGam® COVID-19 Clinical
Trial in Spain

Entera Health, in cooperation with Lemus Buhils, received IRB approval to conduct a clinical trial in Barcelona, Spain using EnteraGam® to manage inflammation and the symptoms associated with COVID-19 infections.

Entera Health Partnerships

By developing unique and exclusive ingredients, with proven clinical efficacy to help support gastrointestinal function, Entera Health and our experts offer unparalleled support to our partners. Thanks to our manufacturing facilities in the United States and New Zealand, we’re able to readily meet consumer demand in new markets worldwide. Find out how you could work with us!